The effect of intravitreal anti-VEGF injections on choroidal vascular index in patients with diabetic macular edema.

IF 1.6 4区 医学 Q3 OPHTHALMOLOGY Cutaneous and Ocular Toxicology Pub Date : 2024-09-01 Epub Date: 2024-07-19 DOI:10.1080/15569527.2024.2380325
Aydin Toprak, Hakan Koc, Atilla Alpay, Suat Hayri Ugurbas
{"title":"The effect of intravitreal anti-VEGF injections on choroidal vascular index in patients with diabetic macular edema.","authors":"Aydin Toprak, Hakan Koc, Atilla Alpay, Suat Hayri Ugurbas","doi":"10.1080/15569527.2024.2380325","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>This study aims to examine and compare the effects of intravitreal bevacizumab injection (IVB) at subfoveal 1500 micron (μm) and submacular 6000 μm in patients with diabetic macular edema (DME).</p><p><strong>Methods: </strong>Fifty eyes of 45 patients with DME who completed six doses of IVB were included in the study group, and 50 eyes of 42 patients who had diabetic retinopathy (DR) but did not receive any treatment were included in the control group. Central macular thickness (CMT), central choroidal thickness (CCT), subfoveal and total choroidal area (TCA), and choroidal vascular index (CVI) were calculated and their changes at zero, three and six months were evaluated.</p><p><strong>Results: </strong>At baseline, CVI was significantly lower in both the subfoveal and total macular areas in the study group (<i>p</i> = 0.004, <i>p</i> = 0.003). In the study group, a significant decrease was observed in CVI between zero and six months in the subfoveal area (<i>p</i> = 0.001). In the submacular area, the decrease in CVI in the study group was significant between zero to three months and zero to six months. There was moderate correlation between measurements of CVI in the subfoveal and total macular areas (<i>r</i> = 0.66, <i>p</i> < 0.001).</p><p><strong>Conclusion: </strong>These findings indicate that intravitreal bevacizumab injection reduces the CVI and the effects of intravitreal anti-VEGF on CVI emerge earlier and more prominently in the submacular 6000 µm area.</p>","PeriodicalId":11023,"journal":{"name":"Cutaneous and Ocular Toxicology","volume":null,"pages":null},"PeriodicalIF":1.6000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cutaneous and Ocular Toxicology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/15569527.2024.2380325","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/19 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: This study aims to examine and compare the effects of intravitreal bevacizumab injection (IVB) at subfoveal 1500 micron (μm) and submacular 6000 μm in patients with diabetic macular edema (DME).

Methods: Fifty eyes of 45 patients with DME who completed six doses of IVB were included in the study group, and 50 eyes of 42 patients who had diabetic retinopathy (DR) but did not receive any treatment were included in the control group. Central macular thickness (CMT), central choroidal thickness (CCT), subfoveal and total choroidal area (TCA), and choroidal vascular index (CVI) were calculated and their changes at zero, three and six months were evaluated.

Results: At baseline, CVI was significantly lower in both the subfoveal and total macular areas in the study group (p = 0.004, p = 0.003). In the study group, a significant decrease was observed in CVI between zero and six months in the subfoveal area (p = 0.001). In the submacular area, the decrease in CVI in the study group was significant between zero to three months and zero to six months. There was moderate correlation between measurements of CVI in the subfoveal and total macular areas (r = 0.66, p < 0.001).

Conclusion: These findings indicate that intravitreal bevacizumab injection reduces the CVI and the effects of intravitreal anti-VEGF on CVI emerge earlier and more prominently in the submacular 6000 µm area.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
玻璃体内抗血管内皮生长因子注射对糖尿病黄斑水肿患者脉络膜血管指数的影响。
目的:本研究旨在探讨和比较糖尿病性黄斑水肿(DME)患者眼底1500微米和眼底6000微米处静脉注射贝伐单抗(IVB)的效果:研究组包括45名完成6次IVB治疗的DME患者的50只眼睛,对照组包括42名患有糖尿病视网膜病变(DR)但未接受任何治疗的患者的50只眼睛。研究人员计算了黄斑中心厚度(CMT)、脉络膜中心厚度(CCT)、叶下和脉络膜总面积(TCA)以及脉络膜血管指数(CVI),并评估了它们在零个月、三个月和六个月时的变化:基线时,研究组黄斑下和黄斑总面积的脉络膜血管指数均明显降低(p = 0.004,p = 0.003)。在研究组中,从零到六个月期间,观察到眼底区域的 CVI 明显下降(p = 0.001)。在黄斑下区域,研究组的 CVI 在零到三个月和零到六个月之间显著下降。黄斑下区域和黄斑总区域的 CVI 测量值之间存在中度相关性(r = 0.66,p 结论:黄斑下区域和黄斑总区域的 CVI 测量值之间存在中度相关性(r = 0.66,p 结论):这些研究结果表明,玻璃体内注射贝伐单抗可降低 CVI,而且玻璃体内抗 VEGF 对 CVI 的影响更早更明显地出现在黄斑下 6000 µm 区域。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
3.30
自引率
6.20%
发文量
40
审稿时长
1 months
期刊介绍: Cutaneous and Ocular Toxicology is an international, peer-reviewed journal that covers all types of harm to cutaneous and ocular systems. Areas of particular interest include pharmaceutical and medical products; consumer, personal care, and household products; and issues in environmental and occupational exposures. In addition to original research papers, reviews and short communications are invited, as well as concise, relevant, and critical reviews of topics of contemporary significance.
期刊最新文献
Impact of oral isotretinoin on the inflammatory markers: can lymphocyte/HDL-C and platelet/HDL-C ratios be new indicators of inflammation in acne vulgaris patients? The effects of electronic cigarette smoking on retinal nerve fiber layer, ganglion cell layer, inner plexiform layer, and choroidal thickness. Evaluation of the common skin diseases in patients with malignancies and the cutaneous side effects of cancer treatments. Ocular toxicities of FDA-approved antibody drug conjugates. Choroidal structural changes in inactive thyroid eye disease: a cross-sectional analysis of the choroidal vascularity index.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1